VYNE Therapeutics (NASDAQ:VYNE) Shares Set to Reverse Split on Monday, July 27th

VYNE Therapeutics Inc. (NASDAQ:VYNE)’s stock is set to reverse split before the market opens on Monday, July 27th. The 1-50 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 26th.

VYNE Therapeutics Trading Up 0.5%

VYNE opened at $0.90 on Thursday. The stock’s 50 day simple moving average is $0.68 and its 200-day simple moving average is $0.63. The stock has a market cap of $29.96 million, a PE ratio of -2.36 and a beta of 2.00. VYNE Therapeutics has a 1 year low of $0.28 and a 1 year high of $1.59.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Friday, May 15th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%. Equities analysts forecast that VYNE Therapeutics will post -1.1 earnings per share for the current fiscal year.

VYNE Therapeutics Dividend Announcement

The firm also recently declared a special dividend, which will be paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd will be issued a $0.38 dividend.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, VYNE Therapeutics currently has a consensus rating of “Reduce”.

Hedge Funds Weigh In On VYNE Therapeutics

A number of hedge funds have recently modified their holdings of the stock. ADAR1 Capital Management LLC lifted its position in shares of VYNE Therapeutics by 319.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock worth $636,000 after buying an additional 810,108 shares during the period. Rangeley Capital LLC grew its position in VYNE Therapeutics by 18.1% in the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after acquiring an additional 18,064 shares during the period. KVP Capital Advisors LP bought a new stake in VYNE Therapeutics in the fourth quarter valued at $290,000. XTX Topco Ltd acquired a new position in VYNE Therapeutics during the fourth quarter worth $46,000. Finally, Anson Funds Management LP acquired a new position in VYNE Therapeutics during the fourth quarter worth $739,000. 83.78% of the stock is owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.